What is the USPSTF position on BRCA1/2 risk assessment in women with personal or family history?

What is the USPSTF position on BRCA1/2 risk assessment in women with personal or family history?

• A. The clinician should assess risk using a brief familial risk assessment tool; positive results lead to genetic counseling and possibly testing
• B. Genetic testing should be offered to all women with any family history of cancer
• C. No risk assessment is necessary for BRCA-related cancer
• D. Genetic testing should be offered only after a full genome sequencing

Answer: (B)

The key idea is to use a risk-based approach to BRCA1/2 assessment rather than testing everyone. Clinicians should screen women who have a personal or family history of breast, ovarian, tubal, or primary peritoneal cancer with a brief, validated risk assessment tool. If the tool identifies increased risk, the next step is referral for genetic counseling, where BRCA testing can be discussed and pursued if appropriate. This target-and-counsel approach aims to identify those most likely to have a pathogenic BRCA1/2 variant and who could benefit from informed decision-making and potential preventive options. Testing all women with any family history would enroll many low-risk individuals and expose them to unnecessary testing and possible harms. No risk assessment overlooks people who might be at increased risk, and requiring full genome sequencing before testing is not aligned with how the guidance recommends proceeding.

The key idea is to use a risk-based approach to BRCA1/2 assessment rather than testing everyone. Clinicians should screen women who have a personal or family history of breast, ovarian, tubal, or primary peritoneal cancer with a brief, validated risk assessment tool. If the tool identifies increased risk, the next step is referral for genetic counseling, where BRCA testing can be discussed and pursued if appropriate. This target-and-counsel approach aims to identify those most likely to have a pathogenic BRCA1/2 variant and who could benefit from informed decision-making and potential preventive options.

Testing all women with any family history would enroll many low-risk individuals and expose them to unnecessary testing and possible harms. No risk assessment overlooks people who might be at increased risk, and requiring full genome sequencing before testing is not aligned with how the guidance recommends proceeding.